Transferability of indirect cost of chronic disease: A systematic review and meta-analysis

PharmacoEconomics

Volumn 31, Issue 6, 2013, Pages 501-508

  Zhao, Fei Li ^a   Xie, Feng ^b,c   Hu, Hao ^d   Li, Shu Chuen ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTHMA; COST OF ILLNESS; DIABETES MELLITUS; ECONOMIC EVALUATION; EMBASE; GROSS NATIONAL PRODUCT; HEALTH CARE COST; INFORMATION RETRIEVAL; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

ARTHRITIS, RHEUMATOID; ASTHMA; CHRONIC DISEASE; COST OF ILLNESS; DIABETES MELLITUS; FEASIBILITY STUDIES; GROSS DOMESTIC PRODUCT; HUMANS; LINEAR MODELS; MODELS, ECONOMIC; SCHIZOPHRENIA;

EID: 84878831007     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0053-6     Document Type: Review

References (28)

1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2006.
2. Knies S, Severens JL, Ament AJ, Evers SM. The transferability of valuing lost productivity across jurisdictions. Differences between national pharmacoeconomic guidelines. Value Health. 2010;13(5):519-27.
3. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12(4):409-18.
4. Barbieri M, Drummond M, Rutten F, Cook J, Glick HA, Lis J, et al. What do international pharmacoeconomic guidelines say about economic data transferability? Value Health. 2010;13(8):1028-37.
5. Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, Towse A. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health. 2005;8(1):10-23.
6. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess. 2004;8(49):iii-iv, 1-192.
7. Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics. 2005;23(3):243-57.
8. Arredondo A, Zuniga A. Economic consequences of epidemiological changes in diabetes in middle-income countries: the Mexican case. Diabetes Care. 2004;27(1):104-9.
9. van Roijen L, Koopmanschap MA, Rutten FF, van der Maas PJ. Indirect costs of disease; an international comparison. Health Policy. 1995;33(1):15-29.
10. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998;13(1 Pt 1):1-7.
11. Koopmanschap MA, Rutten FF. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics. 1993;4(6):446-54.
12. Krol M, Papenburg J, Koopmanschap M, Brouwer W. Do productivity costs matter? the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics. 2011;29(7):601-19.
13. Xie F, Thumboo J, Li SC. True difference or something else? Problems in cost of osteoarthritis studies. Semin Arthritis Rheum. 2007;37(2):127-32.
14. Xie F. The need for standardization: a literature review of indirect costs of rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 2008;59(7):1027-33.
15. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med. 1997;127(5):380-7.
16. International Monetary Fund. World economic outlook database. October 2009 edition. Washington, DC: International Monetary Fund; 2009. http://www.imf.org/external/pubs/ft/weo/2009/02/weodata/index.aspx. Accessed 6 Jan 2011.
17. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. 2nd ed. New York: Oxford University Press; 2000.
18. Efron B. Bootstrap methods: another look at the jacknife. Annu Statist. 1979;7(1):1-26.
19. Adams DC, Gurevitch J, Rosengerg MS. Resampling tests for meta-analysis of ecological data. Ecology. 1997;78(5):1277-83.
20. Lai CKW, Kim YY, Kuo SH, Spencer M, Williams AE. Cost of asthma in the Asia-Pacific region. Eur Respir Rev. 2006;15(98):10-6.
21. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12(6):1322-6.
22. Abel AB, Bernanke BS, Croushore D. Macroeconomics. 6th ed. Boston: Addison Wesley; 2007.
23. Boonen A, van der Heijde D, Landewé R, Spoorenberg A, Schouten H, Rutten-van Mölken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002;61:429-37.
24. Koopmanschap MA, Rutten FF. The consequence of production loss or increased costs of production. Med Care. 1996;34(12 Suppl):DS59-68.
25. Marin-Martinez F, Sanchez-Meca J. Weighting by inverse variance or by sample size in random-effects meta-analysis. Educ Psychol Meas. 2010;70(56):56-73.
26. Liu GG, Eggleston K, Hu TW. Emerging health economics and outcomes research in the Asia-Pacific region. Value Health. 2008;11(Suppl 1):S1-2.
27. Doherty J, Kamae I, Lee KK, Li H, Li SC, Liu GG, et al. What is next for pharmacoeconomics and outcomes research in Asia? Value Health. 2004;7(2):118-32.
28. Koopmanschap M, Burdorf A, Jacob K, Meerding W, Brouwer W, Severens H. Measuring productivity changes in economic evaluation: setting the research agenda. Pharmacoeconomics. 2005;23:47-54.